Urogenital Neoplasms clinical trials at UC Cancer
1 research study open to eligible people
Showing trials for
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
open to eligible males ages 18 years and up
An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC.
at UCSD UCSF